KRAS and colorectal cancer: Despite the encouraging initial efficacy of KRAS G12C inhibitors, rapid drug resistance inevitably occurs, and EGFR signaling reactivation is one of the main resistance mechanisms to KRAS G12C inhibitors in patients with colorectal cancer.